Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
Not wanting to be caught...
New Report: Society Pass (SOPA), Our #1 Internet Company Trading Under $5.00.
Our #1 Internet Company Trading Under $5.00, Society Pass Holds Appeal for Both Traders and Long-Term Investors.
Telehealth App Hapbee (HAPB) Goes Public and More.
1. Hapbee (HAPB) $0.30, Going Public.2. Saying Goodbye to Immunomedics (IMMU) $86.3. Adding Biosig (BSGM) $2.95, to Watch...
Hapbee’s (HAPB) Device, “Choose How You Feel.”
HAPBEE ANNOUNCES LAUNCH OF A SUBSCRIPTION-BASED WELLBEING WEARABLE, PROVIDING MEMBERS THE ABILITY TO CHOOSE 'HOW THEY FEEL'
Proprietary, Research-Backed...
Hapbee’s (HAPB) Revolutionary Sleep Aid, Lands on the Shelves of Target Stores.
When we first came across Hapbee (HAPB) we described it as having a medical technology (a device) that had the "highest potential...
Ehave’s Mobile Ketamine Clinic, Rolling into Town.
Longer term, Ehave's (EHVVF) performance has been a quite a disappointment. Investors grew impatient for the launch...
Smart for Life (SMFL) Reports Revenue Increases 96.9% to $17.8 Million for 2022
Smart for Life Reports 2022 Financial Results and Provides Business Update
(Bolding by IA Editor)
Hapbee (HAPB) Soars 136% the First Day of Trading!
LIVE QUOTE
Subscribe here for upcoming report.
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Institutional Analyst Initiates Coverage on LQR House ‘the Liquor House’ (NASDAQ: LQR).
Report posted below @3:11 11.13.23
LQR House (LQR) $0.09
Easily the Best and Most...